Search results for "Thrombin"

showing 10 items of 201 documents

Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis

2019

Antiphospholipid antibodies (aPLs) with complex lipid and/or protein reactivities cause complement-dependent thrombosis and pregnancy complications. Although cross-reactivities with coagulation regulatory proteins contribute to the risk for developing thrombosis in patients with antiphospholipid syndrome, the majority of pathogenic aPLs retain reactivity with membrane lipid components and rapidly induce reactive oxygen species-dependent proinflammatory signaling and tissue factor (TF) procoagulant activation. Here, we show that lipid-reactive aPLs activate a common species-conserved TF signaling pathway. aPLs dissociate an inhibited TF coagulation initiation complex on the cell surface of m…

Male0301 basic medicineLipoproteinsImmunologyPlenary Paper030204 cardiovascular system & hematologyBiochemistryMonocytesThromboplastinProinflammatory cytokine03 medical and health sciencesTissue factor0302 clinical medicineTissue factor pathway inhibitorThrombinimmune system diseasesmedicineAnimalsHumansThromboplastinBlood CoagulationneoplasmsCells CulturedNADPH oxidasebiologyChemistryThrombosisCell BiologyHematologyComplement systemMice Inbred C57BL030104 developmental biologyAntibodies Antiphospholipidbiology.proteinCancer researchFemaleSignal transductionSignal Transductionmedicine.drugBlood
researchProduct

Mediterranean Diet and atherothrombosis biomarkers: a randomized controlled trial

2020

Scope To assess whether following a Mediterranean diet (MedDiet) improves atherothrombosis biomarkers in high cardiovascular risk individuals. Methods and results In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, the 1‐year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet‐VOO; n = 120) or nuts (MedDiet‐Nuts; n = 119) versus a low‐fat control diet (n = 119), and whether large increments in MedDiet adherence (≥3 score points, versus compliance decreases) and intake changes in key food items are associated with 1‐year differences in biomarkers. Differences are observed between 1‐year changes in the MedDiet‐VOO…

Male0301 basic medicineMediterranean dietProcessed meat intakeAtherothrombosisDiet MediterraneanFibrinogenGastroenterologyCardiovascular riskslaw.inventionFood groupEatingchemistry.chemical_compoundClinical trialsRandomized controlled triallawPlateletNitriteAged 80 and overchemistry.chemical_classificationAntithrombinMiddle AgedThrombosisCardiovascular diseasesBiomarker (medicine)FemaleDietaLipoproteins HDLBiotechnologymedicine.drugcardiovascular riskmedicine.medical_specialty03 medical and health sciencesFatty fishMediterranean cookingThrombinMediterranean dietInternal medicineCuina mediterràniamedicineHumansOlive OilAged030109 nutrition & dieteticsMalalties cardiovascularsbusiness.industryFatty acidThrombosisAtherosclerosismedicine.diseaseConfidence intervalDietCross-Sectional Studies030104 developmental biologyEndocrinologychemistryalpha 1-AntitrypsinbusinessBiomarkersFood Science
researchProduct

Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observa…

2020

Background: The pathogenesis of arterial and venous thrombosis is in large part interlaced. How much platelet phenotype relates to acute venous thromboembolism (VTE) independent of the underlying cardiovascular profile is presently poorly investigated.Methods: Platelet count and mean platelet volume (MPV), platelet aggregation in whole blood and platelet rich plasma (PRP), platelet-dependent thrombin generation (TG) and platelet surface activation markers were measured under standardized conditions. Machine learning was applied to identify the most relevant characteristics associated with VTE from a large array (N = 58) of clinical and plateletrelated variables.Findings: VTE cases (N = 159)…

Male0301 basic medicinePlatelet Aggregationlcsh:MedicineDETERMINANTSGastroenterologyMachine LearningPathogenesisACTIVATION0302 clinical medicineRisk FactorsPlateletWhole bloodlcsh:R5-920AspirinOUTCOMESThrombinVenous ThromboembolismGeneral MedicineMiddle AgedThrombosisVenous thrombosis030220 oncology & carcinogenesisAcute DiseaseFemaleDisease Susceptibilitylcsh:Medicine (General)Research Papermedicine.drugBlood Plateletsmedicine.medical_specialtyPlatelet Function TestsGeneral Biochemistry Genetics and Molecular BiologyImmunophenotyping03 medical and health sciencesACUTE PULMONARY-EMBOLISMRISK-FACTORInternal medicinemedicineHumansMean platelet volumeMETAANALYSISAgedPlatelet Countbusiness.industrylcsh:RPlatelet Activationmedicine.diseasePREVENTIONASPIRINTHROMBOSIS030104 developmental biologyPlatelet-rich plasmaVOLUMEbusinessBiomarkersEBioMedicine
researchProduct

p38 MAPK Controls Prothrombin Expression by Regulated RNA 3′ End Processing

2011

Thrombin is a key protease involved in blood coagulation, complement activation, inflammation, angiogenesis, and tumor invasion. Although induced in many (patho-)physiological conditions, the underlying mechanisms controlling prothrombin expression remained enigmatic. We have now discovered that prothrombin expression is regulated by a posttranscriptional regulatory mechanism responding to stress and inflammation. This mechanism is triggered by external stimuli that activate p38 MAPK. In turn, p38 MAPK upmodulates canonical 3' end processing components and phosphorylates the RNA-binding proteins FBP2 and FBP3, which inhibit 3' end processing of mRNAs, such as prothrombin mRNA, that bear a d…

MaleAdenosinePolymersp38 mitogen-activated protein kinasesInflammationPlasma protein bindingBiologyp38 Mitogen-Activated Protein KinasesGene Expression Regulation EnzymologicMiceThrombinCell Line TumormedicineAnimalsHumansNeoplasm InvasivenessRNA MessengerMolecular BiologyRegulation of gene expressionMessenger RNARNACell BiologyXenograft Model Antitumor AssaysCell biologyRibonucleoproteinsImmunologyPhosphorylationRNAProthrombinmedicine.symptomRNA 3' End Processingmedicine.drugProtein BindingMolecular Cell
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct

Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction.

2011

Thrombotic risk increases in elderly, therefore, the understanding of the genetic predisposition of hypercoagulability could make the difference in the prevention of venous and/or arterial thrombotic events. Laboratory evaluation of hyperfibrinogenemia, increased Factor VII levels, antiphospholipid antibodies presence and hyperhomocysteinemia are considered to have a consistent high predictivity for arterial thrombophilic diseases. Anyway, a large debate exists on the validity of testing Leiden Factor V (FV) G1691A and/or prothrombin (FII) G20210A polymorphisms in patients affected by arterial thrombotic diseases, despite of the several observations described. Here we report data strongly s…

MaleAgingmedicine.medical_specialtyHyperhomocysteinemiaLeiden Factor V; Prothrombin; Stroke; Guidelines; Arterial thrombosis.Myocardial InfarctionHyperfibrinogenemiaGuidelineGUIDELINESGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicineArterial DisorderGenotypeGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAgedAged 80 and overPolymorphism GeneticFactor VIIbusiness.industryFactor VMiddle Agedmedicine.diseaseSurgeryStrokeTHROMBOSISchemistryArterial thrombosis.Prothrombin G20210AFemaleProthrombinGeriatrics and GerontologybusinessGerontologyLeiden Factor V
researchProduct

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

The Cerebral Thrombin System Is Activated after Intracerebral Hemorrhage and Contributes to Secondary Lesion Growth and Poor Neurological Outcome in …

2020

With increasing evidence for the existence of a cerebral thrombin system, coagulation factor IIa (thrombin) is suspected to influence the pathogenesis of secondary injury progression after intracerebral hemorrhage (ICH). We hypothesized that mechanisms associated with local volume expansion after ICH, rather than blood constituents, activate the cerebral thrombin system and are responsible for detrimental neurological outcome. To test this hypothesis, we examine the local thrombin expression after ICH in a C57BL/6N mouse model in the presence and absence of blood constituents. ICH was established using stereotaxic orthotopic injection of utologous blood (

MaleC57BL/6030506 rehabilitationPathologymedicine.medical_specialtyPathogenesisMice03 medical and health sciences0302 clinical medicineThrombinAnimalsMedicineFactor IIaBlood CoagulationCells CulturedCerebral HemorrhageNeuronsIntracerebral hemorrhagebiologybusiness.industryThrombinbiology.organism_classificationmedicine.diseaseMice Inbred C57BLCoagulationCerebrovascular CirculationSecondary LesionNeurology (clinical)0305 other medical sciencebusiness030217 neurology & neurosurgerycirculatory and respiratory physiologymedicine.drugJournal of Neurotrauma
researchProduct

Fibrinogen Naples I (Bβ A68T) Nonsubstrate Thrombin-Binding Capacities

2001

Fibrinogen Naples I (Bbeta A68T) is characterized by defective thrombin binding and fibrinopeptide cleavage at the fibrinogen substrate site in the E domain. We evaluated the fibrinogen of three homozygotic members of this kindred (II.1, II.2, II.3) who have displayed thrombophilic phenotypes and two heterozygotic subjects (I.1, I.2) who were asymptomatic. Electron microscopy of Naples I fibrin networks showed relatively wide fiber bundles, probably due to slowed fibrin assembly secondary to delayed fibrinopeptide release. We evaluated 125I-thrombin binding to the fibrin from subjects I.1, I.2, II.1, and II.2 by Scatchard analysis with emphasis on the high-affinity site in the D domain of f…

MaleCleavage (embryo)FibrinogenFibrinEpitopeRadioligand AssayThrombinmedicineHumansFibrinopeptideBinding siteFamily Healthchemistry.chemical_classificationFibrinBinding SitesbiologyFibrinogens AbnormalThrombinSequence Analysis DNAHematologyMolecular biologyEnzymeBiochemistrychemistryMicroscopy Electron Scanningbiology.proteinFemaleProtein Bindingmedicine.drugThrombosis Research
researchProduct